Search

Your search keyword '"Dalla Gasperina, D"' showing total 97 results
Start Over Author "Dalla Gasperina, D"
97 results on '"Dalla Gasperina, D"'

3. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals

Author

Abbo, L., Abgueguen, P., Almirante, B., Azzini, A.M., Bani-Sadr, F., Bassetti, M., Ben-Ami, R., Beović, B., Béraud, G., Botelho-Nevers, E., Bou, G., Boutoille, D., Cabié, A., Cacopardo, B., Cascio, A., Cassir, N., Castelli, F., Cecala, M., Charmillon, A., Chirouze, C., Cisneros, J.M., Colmenero, J.D., Coppola, N., Corcione, S., Daikos, G.L., Dalla Gasperina, D., De la Calle Cabrera, C., Delobel, P., Di Caprio, D., Durante Mangoni, E., Dupon, M., Ettahar, N., Falagas, M.E., Falcone, M., Fariñas, M.C., Faure, E., Forestier, E., Foti, G., Gallagher, J., Gattuso, G., Gendrin, V., Gentile, I., Giacobbe, D.R., Gogos, C.A., Grandiere Perez, L., Hansmann, Y., Horcajada, J.P., Iacobello, C., Jacob, J.T., Justo, J.A., Kernéis, S., Komnos, A., Kotnik Kevorkijan, B., Lebeaux, D., Le Berre, R., Lechiche, C., Le Moxing, V., Lescure, F.X., Libanore, M., Martinot, M., Merino de Lucas, E., Mondain, V., Mondello, P., Montejo, M., Mootien, J., Muñoz, P., Nir-Paz, R., Pan, A., Paño-Pardo, J.R., Patel, G., Paul, M., Pérez Rodríguez, M.T., Piroth, L., Pogue, J., Potoski, B.A., Pourcher, V., Pyrpasopoulou, A., Rahav, G., Rizzi, M., Rodríguez-Baño, J., Salavert, M., Scheetz, M., Sims, M., Spahija, G., Stefani, S., Stefos, A., Tamma, P.D., Tattevin, P., Tedesco, A., Torre-Cisneros, J., Tripolitsioti, P., Tsiodras, S., Uomo, G., Verdon, R., Viale, P., Vitrat, V., Weinberger, M., Wiener-Well, Y., Papst, L., Pulcini, C., Durante-Mangoni, E., Kaye, K.S., and Raka, L.

Published
2018
Full Text
View/download PDF

4. Indocyanine green angiography for quality assessment of renal graft before transplantation: a pilot study

Author

Ietto, G., Iori, V., Inversini, D., Parise, C., Zani, E., Iovino, D., Tozzi, M., Dalla Gasperina, D., Carcano, G., Franchi, C., Liepa, L., Brusa, D., Masci, F., Morabito, M., Ripamonti, M., Gritti, M., Maierruth, D., and Grappolini, N.

Subjects
Transplantation, Fluorescence intensity, Hypothermic machine perfusion, Kidney transplant, Fluorescence intensity, Kidney transplant, Hypothermic machine perfusion
Published
2023

11. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals

Author

Papst, Lea, Beović, Bojana, Pulcini, Céline, Durante-Mangoni, Emanuele, Rodríguez-Baño, Jesús, Kaye, Keith S, Daikos, George L, Raka, Lul, Paul, Mical, Esgap, Esgbis, ESGIE and the CRGNB treatment survey study group collaborators: Abbo, L, Abgueguen, P, Almirante, B, Azzini, Am, Bani-Sadr, F, Bassetti, M, Ben-Ami, R, Beović, B, Béraud, G, Botelho-Nevers, E, Bou, G, Boutoille, D, Cabié, A, Cacopardo, B, Cascio, A, Cassir, N, Castelli, F, Cecala, M, Charmillon, A, Chirouze, C, Cisneros, Jm, Colmenero, Jd, Coppola, N, Corcione, S, Daikos, Gl, Dalla Gasperina, D, De la Calle Cabrera, C, Delobel, P, Di Caprio, D, Durante Mangoni, E, Dupon, M, Ettahar, N, Falagas, Me, Falcone, M, Fariñas, Mc, Faure, E, Forestier, E, Foti, G, Gallagher, J, Gattuso, G, Gendrin, V, Gentile, I, Giacobbe, Dr, Gogos, Ca, Grandiere Perez, L, Hansmann, Y, Horcajada, Jp, Iacobello, C, Jacob, Jt, Justo, Ja, Kernéis, S, Komnos, A, Kotnik Kevorkijan, B, Lebeaux, D, Le Berre, R, Lechiche, C, Le Moing, V, Lescure, Fx, Libanore, M, Martinot, M, Merino de Lucas, E, Mondain, V, Mondello, P, Montejo, M, Mootien, J, Muñoz, P, Nir-Paz, R, Pan, A, Paño-Pardo, Jr, Patel, G, Paul, M, Pérez Rodríguez MT, Piroth, L, Pogue, J, Potoski, Ba, Pourcher, V, Pyrpasopoulou, A, Rahav, G, Rizzi, M, Rodríguez-Baño, J, Salavert, M, Scheetz, M, Sims, M, Spahija, G, Stefani, S, Stefos, A, Tamma, Pd, Tattevin, P, Tedesco, A, Torre-Cisneros, J, Tripolitsioti, P, Tsiodras, S, Uomo, G, Verdon, R, Viale, P, Vitrat, V, Weinberger, M, Wiener-Well, Y, Papst L., Beovic B., Pulcini C., Durante-Mangoni E., Rodriguez-Bano J., Kaye K.S., Daikos G.L., Raka L., Paul M., Abbo L., Abgueguen P., Almirante B., Azzini A.M., Bani-Sadr F., Bassetti M., Ben-Ami R., Beraud G., Botelho-Nevers E., Bou G., Boutoille D., Cabie A., Cacopardo B., Cascio A., Cassir N., Castelli F., Cecala M., Charmillon A., Chirouze C., Cisneros J.M., Colmenero J.D., Coppola N., Corcione S., Dalla Gasperina D., De la Calle Cabrera C., Delobel P., Di Caprio D., Durante Mangoni E., Dupon M., Ettahar N., Falagas M.E., Falcone M., Farinas M.C., Faure E., Forestier E., Foti G., Gallagher J., Gattuso G., Gendrin V., Gentile I., Giacobbe D.R., Gogos C.A., Grandiere Perez L., Hansmann Y., Horcajada J.P., Iacobello C., Jacob J.T., Justo J.A., Kerneis S., Komnos A., Kotnik Kevorkijan B., Lebeaux D., Le Berre R., Lechiche C., Le Moxing V., Lescure F.X., Libanore M., Martinot M., Merino de Lucas E., Mondain V., Mondello P., Montejo M., Mootien J., Munoz P., Nir-Paz R., Pan A., Pano-Pardo J.R., Patel G., Perez Rodriguez M.T., Piroth L., Pogue J., Potoski B.A., Pourcher V., Pyrpasopoulou A., Rahav G., Rizzi M., Salavert M., Scheetz M., Sims M., Spahija G., Stefani S., Stefos A., Tamma P.D., Tattevin P., Tedesco A., Torre-Cisneros J., Tripolitsioti P., Tsiodras S., Uomo G., Verdon R., Viale P., Vitrat V., Weinberger M., Wiener-Well Y., University Medical Centre Ljubljana [Ljubljana, Slovenia] (UMCL), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Monaldi Hospital, Hospital Virgen Macarena, University of Michigan Medical School [Ann Arbor], University of Michigan [Ann Arbor], University of Michigan System-University of Michigan System, National and Kapodistrian University of Athens (NKUA), University Clinical Center of Kosova, Rambam Health Care Campus, Jackson Memorial Hospital, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Vall d'Hebron University Hospital [Barcelona], University of Verona (UNIVR), Centre Hospitalier Universitaire de Reims (CHU Reims), Ospedale 'Santa Maria della Misericordia' = University Hospital 'Santa Maria della Misericordia', Tel Aviv Sourasky Medical Centre, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Hospital Universitario, A Coruña, Centre hospitalier universitaire de Nantes (CHU Nantes), CHU de la Martinique [Fort de France], ARNAS 'Garibaldi, S. Luigi-Currò, Ascoli-Tomaselli', Università degli studi di Palermo - University of Palermo, Assistance Publique-Hôpitaux de Marseille (AP-HM), ASST Spedali Civili of Brescia, ARNAS Civico Palermo, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Hospital Universitario Virgen del Rocío [Sevilla], Hospital Regional Universitario de Málaga [Spain], Università degli studi della Campania 'Luigi Vanvitelli', University of Turin, University of Insubria, Varese, Hospital Clínic de Barcelona, Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], AO San Sebastiano, CHU Bordeaux [Bordeaux], CH Valenciennes, Henry Dunant Hospital, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Hospital Marques de Valdecillas, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Métropole Savoie [Chambéry], Ospedale di Reggio Calabria, Children’s Hospital of Philadelphia (CHOP ), Carlo Poma Hospital Mantova (ASST Mantova ), CH Belfort-Montbéliard, University of Naples Federico II, AUO San Martino IST Ist Nazl Ric Canc, I-16132 Genoa, Italy, University of Patras [Patras], Centre Hospitalier Le Mans (CH Le Mans), CHU Strasbourg, IMIM-Hospital del Mar, Generalitat de Catalunya, Cannizzaro Hospital, Emory University School of Medicine, Emory University [Atlanta, GA], University of South Carolina [Columbia], AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), General Hospital of Larissa, University medical centre Maribor (UKC Maribor), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), AP-HP - Hôpital Bichat - Claude Bernard [Paris], University of Ferrara at St. Anna Hospital, CH Colmar, Hospital General Universitario de Alicante, CHU Nice [Cimiez], Hôpital Cimiez [Nice] (CHU), AOU Policlinico 'G. Martino', Messina, Italy, Hospital Universitario Cruces = Cruces University Hospital, Centre Hospitalier Emile Muller [Mulhouse] (CH E.Muller Mulhouse), Groupe Hospitalier de Territoire Haute Alsace (GHTHA), Hospital General Universitario 'Gregorio Marañón' [Madrid], Hadassah Hebrew University Medical Center [Jerusalem], Azienda Istituti Ospitalieri di Cremona, Lozano Blesa Clinical Hospital [Zaragoza, Spain], Mount Sinai Hospital [Toronto, Canada] (MSH), Complejo Hospitalario de Vigo, CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Detroit Medical Center, University of Pittsburgh Medical Center [Pittsburgh, PA, États-Unis] (UPMC), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hippokration General Hospital, Sheba Medical Centre, Ramat Gan, Israel, ASST Papa Giovanni XXIII [Bergamo, Italy], Hospital Universitario La Fe, Valencia, Northwestern Hospital Chicago, Beaumont Hospital, Lagjia e Universitetit, Rruga 1, nr.32, 10000 Prishtina, Kosovo, parent, Università degli studi di Catania [Catania], Larissa University Hospital, Johns Hopkins University School of Medicine [Baltimore], CHU Pontchaillou [Rennes], Ospedale Fracastoro San Bonifacio [Verona], Hospital Reina Sofia, Cordoba, Agioi Anargiroi Hospital, Attikon University Hospital, Ospedale Cardarelli, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), CH Annecy Genevois, Assah Harofeh Medical Centre, Zerifin, Israel, Shaare Zedek Medical Centre, Jerusalem, Israel, National Institutes of Health (US), Instituto de Salud Carlos III, Ministerio de Economía, Industria y Competitividad (España), Red Española de Investigación en Patología Infecciosa, European Commission, Papst, Lea, Beović, Bojana, Pulcini, Céline, Durante-Mangoni, Emanuele, Rodríguez-Baño, Jesú, Kaye, Keith S, Daikos, George L, Raka, Lul, Paul, Mical, Papst, L., Beovic, B., Pulcini, C., Durante-Mangoni, E., Rodriguez-Bano, J., Kaye, K. S., Daikos, G. L., Raka, L., Paul, M., Abbo, L., Abgueguen, P., Almirante, B., Azzini, A. M., Bani-Sadr, F., Bassetti, M., Ben-Ami, R., Beraud, G., Botelho-Nevers, E., Bou, G., Boutoille, D., Cabie, A., Cacopardo, B., Cascio, A., Cassir, N., Castelli, F., Cecala, M., Charmillon, A., Chirouze, C., Cisneros, J. M., Colmenero, J. D., Coppola, N., Corcione, S., Dalla Gasperina, D., De la Calle Cabrera, C., Delobel, P., Di Caprio, D., Dupon, M., Ettahar, N., Falagas, M. E., Falcone, M., Farinas, M. C., Faure, E., Forestier, E., Foti, G., Gallagher, J., Gattuso, G., Gendrin, V., Gentile, I., Giacobbe, D. R., Gogos, C. A., Grandiere Perez, L., Hansmann, Y., Horcajada, J. P., Iacobello, C., Jacob, J. T., Justo, J. A., Kerneis, S., Komnos, A., Kotnik Kevorkijan, B., Lebeaux, D., Le Berre, R., Lechiche, C., Le Moxing, V., Lescure, F. X., Libanore, M., Martinot, M., Merino de Lucas, E., Mondain, V., Mondello, P., Montejo, M., Mootien, J., Munoz, P., Nir-Paz, R., Pan, A., Pano-Pardo, J. R., Patel, G., Perez Rodriguez, M. T., Piroth, L., Pogue, J., Potoski, B. A., Pourcher, V., Pyrpasopoulou, A., Rahav, G., Rizzi, M., Salavert, M., Scheetz, M., Sims, M., Spahija, G., Stefani, S., Stefos, A., Tamma, P. D., Tattevin, P., Tedesco, A., Torre-Cisneros, J., Tripolitsioti, P., Tsiodras, S., Uomo, G., Verdon, R., Viale, P., Vitrat, V., Weinberger, M., Wiener-Well, Y., Università degli studi di Verona = University of Verona (UNIVR), Assistance Publique - Hôpitaux de Marseille (APHM), Hospital Regional Universitario de Málaga = Regional University Hospital of Malaga [Spain], and Università degli studi di Torino = University of Turin (UNITO)

Subjects
0301 basic medicine, Acinetobacter baumannii, Carbapenem, Antibiotics, Drug Resistance, Drug resistance, Tigecycline, Carbapenem-resistant Gram-negative bacilli, Combination therapy, Enterobacteriaceae, Polymyxin, Pseudomonas aeruginosa, Survey, 0302 clinical medicine, Surveys and Questionnaires, polycyclic compounds, 030212 general & internal medicine, Anti-Bacterial Agents, Carbapenems, Cross Infection, Cross-Sectional Studies, Drug Resistance, Bacterial, Gram-Negative Bacteria, Gram-Negative Bacterial Infections, Hospitals, Humans, Microbial Sensitivity Tests, Microbiology (medical), Infectious Diseases, biology, Microbial Sensitivity Test, Bacterial, antibiotic management, carbapenem-resistant Gram-negative bacteria, General Medicine, 3. Good health, medicine.drug, Human, medicine.medical_specialty, medicine.drug_class, 030106 microbiology, Fosfomycin, carbapenem-resistant Gram-negative bacteria, 03 medical and health sciences, Hospital, Internal medicine, Anti-Bacterial Agent, medicine, Gram-Negative Bacterial Infection, Cross-Sectional Studie, business.industry, biochemical phenomena, metabolism, and nutrition, biology.organism_classification, bacterial infections and mycoses, Infectious disease (medical specialty), Carbapenem-resistant gram-negative bacilli, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, antibiotic management, business, Rifampicin
Abstract

ESGAP, ESGBIS, ESGIE and the CRGNB treatment survey study group., [Objectives] To explore contemporary antibiotic management of infections caused by carbapenem-resistant Gram-negative bacteria in hospitals., [Methods] Cross-sectional, internet-based questionnaire survey. We contacted representatives of all hospitals with more than 800 acute-care hospital beds in France, Greece, Israel, Italy, Kosovo, Slovenia, Spain and selected hospitals in the USA. We asked respondents to describe the most common actual practice at their hospital regarding management of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa through close-ended questions., [Results] Between January and June 2017, 115 of 141 eligible hospitals participated (overall response rate 81.6%, country-specific rates 66.7%–100%). Most were tertiary-care (99/114, 86.8%), university-affiliated (110/115, 89.1%) hospitals and most representatives were infectious disease specialists (99/115, 86.1%). Combination therapy was prescribed in 114/115 (99.1%) hospitals at least occasionally. Respondents were more likely to consider combination therapy when treating bacteraemia, pneumonia and central nervous system infections and for Enterobacteriaceae, P. aeruginosa and A. baumannii similarly. Combination of a polymyxin with a carbapenem was used in most cases, whereas combinations of a polymyxin with tigecycline, an aminoglycoside, fosfomycin or rifampicin were also common. Monotherapy was used for treatment of complicated urinary tract infections, usually with an aminoglycoside or a polymyxin. The intended goal of combination therapy was to improve the effectiveness of the treatment and to prevent development of resistance. In general, respondents shared the misconception that combination therapy is supported by strong scientific evidence., [Conclusions] Combination therapy was the preferred treatment strategy for infections caused by carbapenem-resistant Gram-negative bacteria among hospital representatives, even though high-quality evidence for carbapenem-based combination therapy is lacking., EDM received funding by NIH for project HHSN272201000039C. JRB received funding for research from Plan Nacional de I + D + i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001)—co-financed by European Development Regional Fund A way to achieve Europe, Operative Programme Intelligent Growth 2014–2020.

Published
2018

15. Italian epidemiology of Gram negative bloodstream infections over 4-year period

Author

Giannella, M, Pascale, R, Tedeschi, S, Bartoletti, M, Ambretti, S, Giacobbe, Dr, Corcione, S, Peghin, M, Mularoni, A, Granata, G, Dalla Gasperina, D, Marchese, V, Lagi, F, Grossi, P, Bassetti, M, Castelli, F, Bartoloni, A, Tumbarello, M, Viscoli, C, Rossolini, Gm, Petrosillo, N, and Viale, P on behalf of ISGRI-SITA study group

Published
2019

17. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals

Author

Papst, L. Beovic, B. Pulcini, C. Durante-Mangoni, E. Rodríguez-Baño, J. Kaye, K.S. Daikos, G.L. Raka, L. Paul, M. Abbo, L. Abgueguen, P. Almirante, B. Azzini, A.M. Bani-Sadr, F. Bassetti, M. Ben-Ami, R. Béraud, G. Botelho-Nevers, E. Bou, G. Boutoille, D. Cabié, A. Cacopardo, B. Cascio, A. Cassir, N. Castelli, F. Cecala, M. Charmillon, A. Chirouze, C. Cisneros, J.M. Colmenero, J.D. Coppola, N. Corcione, S. Dalla Gasperina, D. De la Calle Cabrera, C. Delobel, P. Di Caprio, D. Dupon, M. Ettahar, N. Falagas, M.E. Falcone, M. Fariñas, M.C. Faure, E. Forestier, E. Foti, G. Gallagher, J. Gattuso, G. Gendrin, V. Gentile, I. Giacobbe, D.R. Gogos, C.A. Grandiere Perez, L. Hansmann, Y. Horcajada, J.P. Iacobello, C. Jacob, J.T. Justo, J.A. Kernéis, S. Komnos, A. Kotnik Kevorkijan, B. Lebeaux, D. Le Berre, R. Lechiche, C. Le Moxing, V. Lescure, F.X. Libanore, M. Martinot, M. Merino de Lucas, E. Mondain, V. Mondello, P. Montejo, M. Mootien, J. Muñoz, P. Nir-Paz, R. Pan, A. Paño-Pardo, J.R. Patel, G. Pérez Rodríguez, M.T. Piroth, L. Pogue, J. Potoski, B.A. Pourcher, V. Pyrpasopoulou, A. Rahav, G. Rizzi, M. Salavert, M. Scheetz, M. Sims, M. Spahija, G. Stefani, S. Stefos, A. Tamma, P.D. Tattevin, P. Tedesco, A. Torre-Cisneros, J. Tripolitsioti, P. Tsiodras, S. Uomo, G. Verdon, R. Viale, P. Vitrat, V. Weinberger, M. Wiener-Well, Y. ESGAP, ESGBIS, ESGIE the CRGNB treatment survey study group

Abstract

Objectives: To explore contemporary antibiotic management of infections caused by carbapenem-resistant Gram-negative bacteria in hospitals. Methods: Cross-sectional, internet-based questionnaire survey. We contacted representatives of all hospitals with more than 800 acute-care hospital beds in France, Greece, Israel, Italy, Kosovo, Slovenia, Spain and selected hospitals in the USA. We asked respondents to describe the most common actual practice at their hospital regarding management of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa through close-ended questions. Results: Between January and June 2017, 115 of 141 eligible hospitals participated (overall response rate 81.6%, country-specific rates 66.7%–100%). Most were tertiary-care (99/114, 86.8%), university-affiliated (110/115, 89.1%) hospitals and most representatives were infectious disease specialists (99/115, 86.1%). Combination therapy was prescribed in 114/115 (99.1%) hospitals at least occasionally. Respondents were more likely to consider combination therapy when treating bacteraemia, pneumonia and central nervous system infections and for Enterobacteriaceae, P. aeruginosa and A. baumannii similarly. Combination of a polymyxin with a carbapenem was used in most cases, whereas combinations of a polymyxin with tigecycline, an aminoglycoside, fosfomycin or rifampicin were also common. Monotherapy was used for treatment of complicated urinary tract infections, usually with an aminoglycoside or a polymyxin. The intended goal of combination therapy was to improve the effectiveness of the treatment and to prevent development of resistance. In general, respondents shared the misconception that combination therapy is supported by strong scientific evidence. Conclusions: Combination therapy was the preferred treatment strategy for infections caused by carbapenem-resistant Gram-negative bacteria among hospital representatives, even though high-quality evidence for carbapenem-based combination therapy is lacking. © 2018 European Society of Clinical Microbiology and Infectious Diseases

Published
2018

28. Pneumonia in solid organ transplant recipients: A prospective multicenter study

Author

Giannella, M, Muñoz, P, Alarcón, Jm, Mularoni, A, Grossi, P, Bouza, E, Ranghino, Andrea, Segoloni, Giuseppe, Durante Mangoni, E, Pinto, D, Utili, R, Maiello, C, Vizzini, G, Gandolfini, I, Maggiore, U, Dalla Gasperina, D, Lappa, A, Musumeci, F, Forni, A, Faggian, G, Giaquinta, A, Veroux, P, Antonelli, B, Rossi, G, Parisi, F, Alfieri, S, Balzano, E, Filipponi, F, Valerio, F, Sandrini, S, Onano, B, Piredda, G, Frascà, Gm, Gaffi, G, Dello Strologo, L, Guzzo, I, Berardinelli, L, Pasciucco, A, Bonofiglio, R, Leone, F, Musso, M, Petrosillo, N, Lopez Medrano, F, Aguado, Jm, Charo, L, de la Torre Cisneros, J, Ulica, Ih, Moreno Camacho, A, Fernandez, Ns, Carratala, J, Eworo, A, Valerio, M, Roca, C, Cordero Matia ME, Arribi Vilela, A, Picazo de la Garza JJ, Portilla Sogorb, J, De Lucas EM, Munoz Sanz, A, Vera Tome, A, Montejo, Jm, Gurgui Ferrer, M, Mirabet, S, Canas, L, Lausturica Valdemoros, R, Silva, I, Guirado, L, Meije Castillo, Y, Fortun Abete, J, Diaz Molina, B, Bernardo Rodriguez MJ, Farinas, C, Luzano, F, and de Valdecilla, M.

Subjects
Graft Rejection, Male, Lung Diseases, Prevalence, Drug Resistance, Organ transplantation, law.invention, Solid organ transplantation, law, Drug Resistance, Multiple, Bacterial, Epidemiology, Medicine, Hospital Mortality, Prospective Studies, Viral, Prospective cohort study, education.field_of_study, Cross Infection, Incidence (epidemiology), Bacterial, Middle Aged, Intensive care unit, Community-Acquired Infections, Infectious Diseases, Fungal, Italy, Female, Multiple, medicine.medical_specialty, Critical Care, Population, Pneumonia, Viral, Health care-associated pneumonia, Internal medicine, Pneumonia, Bacterial, Humans, education, Aged, Transplantation, Lung Diseases, Fungal, business.industry, Pneumonia, Organ Transplantation, medicine.disease, Surgery, Spain, business, health care-associated pneumonia, pneumonia, solid organ transplantation
Abstract

Background Pneumonia frequently affects solid organ transplant (SOT) recipients, with high morbidity and mortality. However, the few studies on pneumonia in this population are mainly retrospective, single-center, and long-term studies, or include patients with only one type of SOT or a specific etiology. We performed a point prevalence study to investigate epidemiology, diagnosis, therapy, and outcome of pneumonia in an unselected SOT population. Methods Italian and Spanish transplant centers were invited to report on all SOT recipients with pneumonia treated during 2 separate weeks (1 each in February and June 2012). Results In total, 35 centers (18 in Italy, 17 in Spain) agreed to participate and collected 54 cases. The incidence of pneumonia was 10.1 episodes/1000 recipients/year. Pneumonia was classified as late (>6 months) in 70.4% of cases. Pneumonia was also classified as community-acquired (CAP), healthcare-associated (HCAP), and hospital-acquired (HAP) pneumonia in 40.7%, 38.9%, and 20.4% of cases, respectively. An attempt to microbiological diagnosis (≥1 sample) was made in 94.4% of patients, with a diagnostic yield of 60.7%. Causative agents included bacteria (87.1%), virus (29%), and fungi (6.4%). A multidrug-resistant bacterium was isolated in 18.2%, 40%, and 100% of patients with CAP, HCAP, and HAP (P = 0.007), respectively. Overall, 11.1% of patients were admitted to the intensive care unit, 3.7% developed graft rejection, and graft function deteriorated in 18.5%. In-hospital mortality was 1.9%. Conclusion Pneumonia remains a frequent problem in SOT recipients, although it occurs later in patients who are in better physical health. Therefore, harmful pathogens and worse outcome are less common than previously thought.

Published
2014

29. Predicting the occurrence of embolic events: An analysis of 1456 episodes of infective endocarditis from the Italian Study on Endocarditis

Author

Rizzi, Marco, Ravasio, Veronica, Carobbio, Alessandra, Mattucci, Irene, Crapis, Massimo, Stellini, Roberto, Pasticci, Maria B., Chinello, Pierangelo, Falcone, Marco, Grossi, Paolo, Barbaro, Francesco, Pan, Angelo, Viale, Pierluigi, Durante, Mangoni, Emanuele, Biglino, A, Brusa MT, Crivelli P, Moglia, R, Leone, S, Ravasio, V, Rizzi, M, Suter, F, Viale, P, Mian, P, Spoladore, G, Castelli, F, Magri, S, Stellini, R, Di Caprio, D, Van Hauwermeiren, E, Pan, A, Zacchi, F, Barzaghi, N, Libanore, M, Pantaleoni, M, Del Bono, V, Viscoli, C, Gattuso, G, Scalzini, A, Villa, Mr, Bernardo, M, Casillo, R, Cuccurullo, S, Dialetto, G, Durante Mangoni, E, Mattucci, I, Ragone, E, Tripodi, Mf, Utili, R, Barbaro, F, Erne, E, Minoli, L, Seminari, Em, Martinelli, L, Pallotto, C, Pasticci, Mb, Canovari, B, Stoppini, L, Chinello, P, Falcone, M, Petrosillo, N, Venditti, M, Delle Foglie, P, Giobbia, M, Inoiosa, W, Scotton, G, Vaglia, A, Bassetti, Matteo, Crapis, M, Venturini, S, Dalla Gasperina, D, Grossi, P, Tebini, A, Concia, E, Del Bravo, P, Tedesco, A, Nicolin, R, Pellizzer, G., Rizzi, M., Ravasio, V., Carobbio, A., Mattucci, I., Crapis, M., Stellini, R., Pasticci, M.B., Chinello, P., Falcone, M., Grossi, P., Barbaro, F., Pan, A, Viale, P, Durante-Mangoni, E., Rizzi, M, Ravasio, V, Carobbio, A, Mattucci, I, Crapis, M, Stellini, R, Pasticci, Mb, Chinello, P, Falcone, M, Grossi, P, Barbaro, F, and DURANTE MANGONI, Emanuele

Subjects
Adult, Male, medicine.medical_specialty, Embolism, infective endocarditis embolic events, Risk Factors, Internal medicine, medicine, Endocarditis, Humans, Risk factor, Prospective cohort study, Aged, Retrospective Studies, Framingham Risk Score, Infective endocarditis, Risk score, Stroke, Endocarditis, Bacterial, Female, Italy, Middle Aged, business.industry, Medicine (all), Bacterial, Retrospective cohort study, Odds ratio, medicine.disease, Surgery, Infectious Diseases, business, Research Article
Abstract

BACKGROUND: Embolic events are a major cause of morbidity and mortality in patients with infective endocarditis. We analyzed the database of the prospective cohort study SEI in order to identify factors associated with the occurrence of embolic events and to develop a scoring system for the assessment of the risk of embolism. METHODS: We retrospectively analyzed 1456 episodes of infective endocarditis from the multicenter study SEI. Predictors of embolism were identified. Risk factors identified at multivariate analysis as predictive of embolism in left-sided endocarditis, were used for the development of a risk score: 1 point was assigned to each risk factor (total risk score range: minimum 0 points; maximum 2 points). Three categories were defined by the score: low (0 points), intermediate (1 point), or high risk (2 points); the probability of embolic events per risk category was calculated for each day on treatment (day 0 through day 30). RESULTS: There were 499 episodes of infective endocarditis (34%) that were complicated by ≥ 1 embolic event. Most embolic events occurred early in the clinical course (first week of therapy: 15.5 episodes per 1000 patient days; second week: 3.7 episodes per 1000 patient days). In the total cohort, the factors associated with the occurrence of embolism at multivariate analysis were prosthetic valve localization (odds ratio, 1.84), right-sided endocarditis (odds ratio, 3.93), Staphylococcus aureus etiology (odds ratio, 2.23) and vegetation size ≥ 13 mm (odds ratio, 1.86). In left-sided endocarditis, Staphylococcus aureus etiology (odds ratio, 2.1) and vegetation size ≥ 13 mm (odds ratio, 2.1) were independently associated with embolic events; the 30-day cumulative incidence of embolism varied with risk score category (low risk, 12%; intermediate risk, 25%; high risk, 38%; p

Published
2014

39. Use of colistin in adult patients: a cross-sectional study

Author

Giacobbe, Daniele Roberto, Saffioti, Carolina, Losito, Angela Raffaella, Rinaldi, Matteo, Aurilio, Caterina, Bolla, Cesare, Boni, Silvia, Borgia, Guglielmo, Carannante, Novella, Cassola, Giovanni, Ceccarelli, Giancarlo, Corcione, Silvia, Gasperina, Daniela Dalla, De Rosa, Francesco Giuseppe, Dentone, Chiara, Di Bella, Stefano, Di Lauria, Nicoletta, Feasi, Marcello, Fiore, Marco, Fossati, Sara, Franceschini, Erica, Gori, Andrea, Granata, Guido, Grignolo, Sara, Grossi, Paolo Antonio, Guadagnino, Giuliana, Lagi, Filippo, Maraolo, Alberto Enrico, Marinò, Valeria, Mazzitelli, Maria, Mularoni, Alessandra, Oliva, Alessandra, Pace, Maria Caterina, Parisini, Andrea, Patti, Francesca, Petrosillo, Nicola, Pota, Vincenzo, Raffaelli, Francesca, Rossi, Marianna, Santoro, Antonella, Tascini, Carlo, Torti, Carlo, Trecarichi, Enrico Maria, Venditti, Mario, Viale, Pierluigi, Signori, Alessio, Del Bono, Valerio, Giannella, Maddalena, Mikulska, Malgorzata, Tumbarello, Mario, Viscoli, Claudio, Passavanti, Maria Beatrice, Rogati, C, Sansone, Pasquale, Sarteschi, G, Roberto Giacobbe, Daniele, Saffioti1, Carolina, Raffaella Losito, Angela, Rinaldi, Matteo, Aurilio, Caterina, Bolla, Cesare, Boni, Silvia, Borgia, Guglielmo, Carannante, Novella, Cassola, Giovanni, Ceccarelli, Giancarlo, Corcione, Silvia, Dalla Gasperina, Daniela, Giuseppe De Rosa, Francesco, Dentone, Chiara, DI BELLA, Stefano, Di Lauria, Nicoletta, Feasi, Marcello, Fiore, Marco, Fossati, Sara, Franceschini, Erica, Gori, Andrea, Granata, Guido, Grignolo, Sara, Antonio Grossi, Paolo, Guadagnino, Giuliana, Lagi, Filippo, Enrico Maraolo, Alberto, Marinò, Valeria, Mazzitelli, Maria, Mularoni, Alessandra, Oliva, Alessandra, Caterina Pace, Maria, Parisini, Andrea, Patti, Francesca, Petrosillo, Nicola, Pota, Vincenzo, Raffaelli, Francesca, Rossi, Marianna, Santoro, Antonella, Tascini, Carlo, Torti, Carlo, Maria Trecarichi, Enrico, Venditti, Mario, Viale, Pierluigi, Signori, Alessio, Bassetti, Matteo, Del Bono, Valerio, Giannella, Maddalena, Mikulska, Malgorzata, Tumbarello, Mario, Viscoli, Claudio, Giacobbe, Daniele Roberto, Saffioti, Carolina, Losito, Angela Raffaella, Gasperina, Daniela Dalla, De Rosa, Francesco Giuseppe, Di Bella, Stefano, Grossi, Paolo Antonio, Maraolo, Alberto Enrico, Pace, Maria Caterina, Trecarichi, Enrico Maria, Passavanti, Maria Beatrice, Rogati, C, Sansone, Pasquale, Sarteschi, G, Giacobbe D.R., Saffioti C., Losito A.R., Rinaldi M., Aurilio C., Bolla C., Boni S., Borgia G., Carannante N., Cassola G., Ceccarelli G., Corcione S., Dalla Gasperina D., De Rosa F.G., Dentone C., Di Bella S., Di Lauria N., Feasi M., Fiore M., Fossati S., Franceschini E., Gori A., Granata G., Grignolo S., Grossi P.A., Guadagnino G., Lagi F., Maraolo A.E., Marino V., Mazzitelli M., Mularoni A., Oliva A., Pace M.C., Parisini A., Patti F., Petrosillo N., Pota V., Raffaelli F., Rossi M., Santoro A., Tascini C., Torti C., Trecarichi E.M., Venditti M., Viale P., Signori A., Bassetti M., Del Bono V., Giannella M., Mikulska M., Tumbarello M., and Viscoli C.

Subjects
0301 basic medicine, Male, Endemic Diseases, Drug Resistance, Carbapenem-resistant enterobacteriaceae, Pseudomona, 0302 clinical medicine, Interquartile range, Levofloxacin, Drug Resistance, Multiple, Bacterial, Klebsiella, polycyclic compounds, Acinetobacter, Antimicrobial resistance, Colistimethate, Colistin, Pseudomonas, Administration, Intravenous, Aged, Anti-Bacterial Agents, Cross-Sectional Studies, Drug Prescriptions, Drug Therapy, Combination, Female, Gram-Negative Bacterial Infections, Humans, Italy, Middle Aged, Respiratory Tract Infections, Sepsis, Immunology and Allergy, 030212 general & internal medicine, colistin, colistimethate, Bacterial, QR1-502, Administration, Combination, lipids (amino acids, peptides, and proteins), antimicrobial resistance, Intravenous, Multiple, medicine.drug, Microbiology (medical), medicine.medical_specialty, Cefepime, 030106 microbiology, Immunology, Microbiology, Loading dose, 03 medical and health sciences, Drug Therapy, Internal medicine, Lower respiratory tract infection, medicine, business.industry, biochemical phenomena, metabolism, and nutrition, medicine.disease, business
Abstract

Objectives The aim of this study was to assess colistin use in a country endemic for multidrug-resistant Gram-negative bacteria (MDR-GNB). Methods Colistin prescription patterns were evaluated in 22 Italian centres. Factors associated with use of colistin in combination with other anti-MDR-GNB agents were also assessed. Results A total of 221 adults receiving colistin were included in the study. Their median age was 64 years (interquartile range 52–73 years) and 134 (61%) were male. Colistin was mostly administered intravenously (203/221; 92%) and mainly for targeted therapy (168/221; 76%). The most frequent indications for colistin therapy were bloodstream infection and lower respiratory tract infection. Intravenous colistin was administered in combination with at least another anti-MDR-GNB agent in 80% of cases (163/203). A loading dose of 9 MU of colistimethate was administered in 79% of patients receiving i.v. colistin and adequate maintenance doses in 85%. In multivariable analysis, empirical therapy [odds ratio (OR) = 3.25, 95% confidence interval (CI) 1.24–8.53;P = 0.017] and targeted therapy for carbapenem-resistant Enterobacterales infection (OR = 4.76, 95% CI 1.69–13.43; P = 0.003) were associated with use of colistin in combination with other agents, whilst chronic renal failure (OR = 0.39, 95% CI 0.17–0.88; P = 0.024) was associated with use of colistin monotherapy. Conclusion Colistin remains an important option for severe MDR-GNB infections when other treatments are not available. Despite inherent difficulties in optimising its use owing to peculiar pharmacokinetic/pharmacodynamic characteristics, colistin was mostly used appropriately in a country endemic for MDR-GNB.

Published
2020

40. The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study

Author

Salerno, Francesco, Borzio, Mauro, Pedicino, Claudia, Simonetti, Rosa, Rossini, Angelo, Boccia, Sergio, Cacciola, Irene, Burroughs, Andrew K., Manini, Matteo A., La Mura, Vincenzo, Angeli, Paolo, Bernardi, Mauro, Dalla Gasperina, Daniela, Dionigi, Elena, Dibenedetto, Clara, Arghittu, Milena, Francavilla, Antonio, Trevisani, Franco, Salmi, Andrea, Fatuzzo, Filippo, Arvaniti, Vassiliki, Cambieri, Patrizia, Raguzzi, Ivana, Aghemo, Alessio, Trotta, Elisa, Cottone, Mario, Perricone, Giovanni, Giusti, Massimo, Cazzaniga, Massimo, Gobbo, Giulia, Monti, Valentina, Tejada, Milvana, Costa, Elena, Andriulli, Angelo, Grossi, Paolo, Salerno, F, Borzio, M, Pedicino, C, Simonetti, R, Rossini, A, Boccia, S, Cacciola, I, Burroughs, Ak, Manini, Ma, La Mura, V, Angeli, P, Bernardi, M, Dalla Gasperina, D, Dionigi, E, Dibenedetto, C, Arghittu, M, and Trevisani, F.

Subjects
Liver Cirrhosis, Male, medicine.medical_specialty, Cirrhosis, bacterial resistance, cirrhosis, portal hypertension, survival, medicine.drug_class, Antibiotics, survival, 03 medical and health sciences, 0302 clinical medicine, Spontaneous bacterial peritonitis, Antibiotic resistance, Drug Resistance, Multiple, Bacterial, Internal medicine, medicine, Humans, Hospital Mortality, Prospective Studies, 030212 general & internal medicine, Prospective cohort study, Aged, Cross Infection, Bacteria, Hepatology, business.industry, cirrhosis, Mortality rate, portal hypertension, Bacterial Infections, bacterial resistance, Middle Aged, Prognosis, medicine.disease, Anti-Bacterial Agents, Surgery, Logistic Models, Italy, Hepatocellular carcinoma, Multivariate Analysis, Female, 030211 gastroenterology & hepatology, business
Abstract

Background & Aims Bacterial strains resistant to antibiotics are a serious clinical challenge. We assessed the antibiotic susceptibility of bacteria isolated from infections in patients with cirrhosis by a multicentre investigation. Results Three hundred and thirteen culture-positive infections (173 community acquired [CA] and 140 hospital acquired [HA]) were identified in 308 patients. Urinary tract infections, spontaneous bacterial peritonitis and bacteremias were the most frequent. Quinolone-resistant Gram-negative isolates were 48%, 44% were extended-spectrum beta-lactamase producers and 9% carbapenem resistant. In 83/313 culture-positive infections (27%), multidrug-resistant agents (MDRA) were isolated. This prevalence did not differ between CA and HA infections. MDRA were identified in 17 of 37 patients on quinolone prophylaxis, and in 46 of 166 not on prophylaxis (45% vs 27%; P

Published
2016

41. COVID-19 detection from exhaled breath.

Author

Bellarmino N, Cantoro R, Castelluzzo M, Correale R, Squillero G, Bozzini G, Castelletti F, Ciricugno C, Dalla Gasperina D, Dentali F, Poggialini G, Salerno P, and Taborelli S

Subjects
Humans, Male, Female, Adult, Middle Aged, Machine Learning, Exhalation, COVID-19 Testing methods, Algorithms, Sensitivity and Specificity, Aged, Mass Spectrometry methods, COVID-19 diagnosis, COVID-19 virology, COVID-19 epidemiology, Breath Tests methods, SARS-CoV-2 isolation & purification
Abstract

The SARS-CoV-2 coronavirus emerged in 2019 causing a COVID-19 pandemic that resulted in 7 million deaths out of 770 million reported cases over the next 4 years. The global health emergency called for unprecedented efforts to monitor and reduce the rate of infection, pushing the study of new diagnostic methods. In this paper, we introduce a cheap, fast, and non-invasive COVID-19 detection system, which exploits only exhaled breath. Specifically, provided an air sample, the mass spectra in the 10-351 mass-to-charge range are measured using an original micro and nano-sampling device coupled with a high-precision spectrometer; then, the raw spectra are processed by custom software algorithms; the clean and augmented data are eventually classified using state-of-the-art machine-learning algorithms. An uncontrolled clinical trial was conducted between 2021 and 2022 on 302 subjects who were concerned about being infected, either due to exhibiting symptoms or having recently recovered from illness. Despite the simplicity of use, our system showed a performance comparable to the traditional polymerase-chain-reaction and antigen testing in identifying cases of COVID-19 (that is, 95% accuracy, 94% recall, 96% specificity, and 92% [Formula: see text]-score). In light of these outcomes, we think that the proposed system holds the potential for substantial contributions to routine screenings and expedited responses during future epidemics, as it yields results comparable to state-of-the-art methods, providing them in a more rapid and less invasive manner., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

42. Torque Teno Virus: A Promising Biomarker in Kidney Transplant Recipients.

Author

Dal Lago S, Brani P, Ietto G, Dalla Gasperina D, Gianfagna F, Giaroni C, Bosi A, Drago Ferrante F, Genoni A, Manzoor HZ, Ambrosini A, De Cicco M, Quartarone CD, Khemara S, Carcano G, Maggi F, and Baj A

Subjects
Humans, Male, Middle Aged, Female, Adult, DNA Virus Infections urine, DNA Virus Infections blood, DNA Virus Infections virology, Prospective Studies, Transplant Recipients, Aged, Torque teno virus, Kidney Transplantation adverse effects, Biomarkers urine, Biomarkers blood, Viral Load
Abstract

Torque Teno Virus (TTV) is a ubiquitous component of the human virome, not associated with any disease. As its load increases when the immune system is compromised, such as in kidney transplant (KT) recipients, TTV load monitoring has been proposed as a method to assess immunosuppression. In this prospective study, TTV load was measured in plasma and urine samples from 42 KT recipients, immediately before KT and in the first 150 days after it. Data obtained suggest that TTV could be a relevant marker for evaluating immune status and could be used as a guide to predict the onset of infectious complications in the follow-up of KT recipients. Since we observed no differences considering distance from transplantation, while we found a changing trend in days before viral infections, we suggest to consider changes over time in the same subjects, irrespective of time distance from transplantation.

Published
2024
Full Text
View/download PDF

43. Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly.

Author

Dalla Gasperina D, Veronesi G, Castelletti CM, Varchetta S, Ottolini S, Mele D, Ferrari G, Shaik AKB, Celesti F, Dentali F, Accolla RS, and Forlani G

Subjects
Aged, Humans, Aged, 80 and over, COVID-19 Vaccines, BNT162 Vaccine, Prospective Studies, Immunoglobulin G, Immunity, Cellular, Frailty, COVID-19 prevention & control
Abstract

Although the safety and efficacy of COVID-19 vaccines in older people are critical to their success, little is known about their immunogenicity among elderly residents of long-term care facilities (LTCFs). A single-center prospective cohort study was conducted: a total IgG antibody titer, neutralizing antibodies against Wild-type, Delta Plus, and Omicron BA.2 variants and T cell response, were measured eight months after the second dose of BNT162b2 vaccine (T0) and at least 15 days after the booster (T1). Forty-nine LTCF residents, with a median age of 84.8 ± 10.6 years, were enrolled. Previous COVID-19 infection was documented in 42.9% of the subjects one year before T0. At T1, the IgG titers increased up to 10-fold. This ratio was lower in the subjects with previous COVID-19 infection. At T1, IgG levels were similar in both groups. The neutralizing activity against Omicron BA.2 was significantly lower (65%) than that measured against Wild-type and Delta Plus (90%). A significant increase of T cell-specific immune response was observed after the booster. Frailty, older age, sex, cognitive impairment, and comorbidities did not affect antibody titers or T cell response. In the elderly sample analyzed, the BNT162b2 mRNA COVID-19 vaccine produced immunogenicity regardless of frailty.

Published
2023
Full Text
View/download PDF

44. Multicellular Liver Organoids: Generation and Importance of Diverse Specialized Cellular Components.

Author

Ietto G, Iori V, Gritti M, Inversini D, Costantino A, Izunza Barba S, Jiang ZG, Carcano G, Dalla Gasperina D, and Pettinato G

Subjects
Humans, Reproducibility of Results, Hepatocytes, Organoids, Endothelial Cells, Liver
Abstract

Over 40,000 patients in the United States are estimated to suffer from end-stage liver disease and acute hepatic failure, for which liver transplantation is the only available therapy. Human primary hepatocytes (HPH) have not been employed as a therapeutic tool due to the difficulty in growing and expanding them in vitro, their sensitivity to cold temperatures, and tendency to dedifferentiate following two-dimensional culture. The differentiation of human-induced pluripotent stem cells (hiPSCs) into liver organoids (LO) has emerged as a potential alternative to orthotropic liver transplantation (OLT). However, several factors limit the efficiency of liver differentiation from hiPSCs, including a low proportion of differentiated cells capable of reaching a mature phenotype, the poor reproducibility of existing differentiation protocols, and insufficient long-term viability in vitro and in vivo. This review will analyze various methodologies being developed to improve hepatic differentiation from hiPSCs into liver organoids, paying particular attention to the use of endothelial cells as supportive cells for their further maturation. Here, we demonstrate why differentiated liver organoids can be used as a research tool for drug testing and disease modeling, or employed as a bridge for liver transplantation following liver failure.

Published
2023
Full Text
View/download PDF

45. Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine.

Author

Azzi L, Dalla Gasperina D, Veronesi G, Shallak M, Maurino V, Baj A, Gianfagna F, Cavallo P, Dentali F, Tettamanti L, Maggi F, Maffioli LS, Tagliabue A, Accolla RS, and Forlani G

Subjects
Humans, BNT162 Vaccine, COVID-19 Vaccines, Antibodies, Neutralizing, Immunoglobulin A, Immunoglobulin G, Antibodies, Viral, Vaccination, Immunity, Mucosal, COVID-19 prevention & control
Abstract

Background: To date, only a few studies reported data regarding the development of mucosal immune response after the BNT162b2-booster vaccination., Methods: Samples of both serum and saliva of 50 healthcare workers were collected at the day of the booster dose (T3) and after two weeks (T4). Anti-S1-protein IgG and IgA antibody titres and the neutralizing antibodies against the Wuhan wild-type Receptor-Binding Domain in both serum and saliva were measured by quantitative and competitive ELISA, respectively. Data were compared with those recorded after the primary vaccination cycle (T2). Neutralizing antibodies against the variants of concern were measured in those individuals with anti-Wuhan neutralizing antibodies in their saliva., Findings: After eight months from the second dose, IgG decreased in both serum (T2 GMC : 23,838.5 ng/ml; T3 GMC : 1473.8 ng/ml) and saliva (T2 GMC : 12.9 ng/ml; T3 GMC : 0.3 ng/ml). Consistently, serum IgA decreased (T2 GMC : 48.6 ng/ml; T3 GMC : 6.4 ng/ml); however, salivary IgA showed a different behaviour and increased (T2 GMC : 0.06 ng/ml; T3 GMC : 0.41 ng/ml), indicating a delayed activation of mucosal immunity. The booster elicited higher titres of both IgG and IgA when compared with the primary cycle, in both serum (IgG T4 GMC : 98,493.9 ng/ml; IgA T4 GMC : 187.5 ng/ml) and saliva (IgG T4 GMC : 21.9 ng/ml; IgA T4 GMC : 0.65 ng/ml). Moreover, the booster re-established the neutralizing activity in the serum of all individuals, not only against the Wuhan wild-type antigen (N = 50; INH: 91.6%) but also against the variants (Delta INH: 91.3%; Delta Plus INH: 89.8%; Omicron BA.1 INH: 85.1%). By contrast, the salivary neutralizing activity was high against the Wuhan antigen in 72% of individuals (N = 36, INH: 62.2%), but decreased against the variants, especially against the Omicron BA.1 variant (Delta N = 27, INH: 43.1%; Delta Plus N = 24, INH: 35.2%; Omicron BA.1 N = 4; INH: 4.7%). This was suggestive for a different behaviour of systemic immunity observed in serum with respect to mucosal immunity described in saliva (Wald chi-square test, 3 df of interaction between variants and sample type = 308.2, p < 0.0001)., Interpretation: The BNT162b2-booster vaccination elicits a strong systemic immune response but fails in activating an effective mucosal immunity against the Omicron BA.1 variant., Funding: This work was funded by the Department of Medicine and Surgery, University of Insubria, and supported by Fondazione Umberto Veronesi (COVID-19 Insieme per la ricerca di tutti, 2020), Italy., Competing Interests: Declaration of interests None to declare., (Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)

Published
2023
Full Text
View/download PDF

46. Attitude towards Intranasal Vaccines and Psychological Determinants: Effects on the General Population in Northern Italy.

Author

Boragno P, Fiabane E, Colledani D, Dalla Gasperina D, Setti I, Sommovigo V, and Gabanelli P

Abstract

Little is known about the use of intranasal vaccines, but some studies have shown that this innovative way of administration is preferred over needle injection as it is considered both less painful and intrusive to the body, equally effective, and associated with fewer side effects. This study aimed to investigate specific psychological determinants (intolerance of uncertainty, persecutory ideation, perceived control, vaccine hesitancy) of attitude toward nasal vaccine delivery. A convenience sample including 700 Italian participants took part in this cross-sectional study and completed an online questionnaire. A structural equation model with a latent variable was performed to study the relationship between psychological variables, vaccine hesitancy, and attitude toward nasal vaccine delivery. The results indicate that both a hesitant attitude toward vaccination ( β = 0.20, p = 0.000) and low perceived control ( β = -0.20, p = 0.005) may directly increase preference for nasal administration; furthermore, high levels of persecutory ideation may indirectly influence the propensity for intranasal vaccine. These findings suggest that pharmaceutical companies could implement nasal vaccines and provide detailed information on these vaccines through informational campaigns. Hesitant individuals with low levels of perceived control could more easily comply with these types of vaccines.

Published
2023
Full Text
View/download PDF

47. Dopaminergic inhibition of human neutrophils is exerted through D1-like receptors and affected by bacterial infection.

Author

Marino F, Pinoli M, Rasini E, Martini S, Luini A, Pulze L, Dalla Gasperina D, Grossi P, Legnaro M, Ferrari M, Congiu T, Pacheco R, Osorio-Barrios F, de Eguileor M, and Cosentino M

Subjects
Humans, Animals, Mice, Neutrophils, Reactive Oxygen Species, Receptors, Dopamine, Receptors, Dopamine D5 genetics, Dopamine, Bacterial Infections
Abstract

Dopamine (DA) affects immune functions in healthy subjects (HS) and during disease by acting on D1-like (D1 and D5) and D2-like (D2, D3 and D4) dopaminergic receptors (DR); however, its effects on human polymorphonuclear leukocytes (PMN) are still poorly defined. We investigated DR expression in human PMN and the ability of DA to affect cell migration and reactive oxygen species (ROS) production. Experiments were performed on cells from HS and from patients (Pts) with bacterial infections as well, during the acute phase and after recovery. Some experiments were also performed in mice knockout (KO) for the DRD5 gene. PMN from HS express both D1-like and D2-like DR, and exposure to DA results in inhibition of activation-induced morphological changes, migration and ROS production which depend on the activation of D1-like DR. In agreement with these findings, DA inhibited migration of PMN obtained from wild-type mice, but not from DRD5KO mice. In Pts with bacterial infections, during the febrile phase D1-like DRD5 on PMN were downregulated and DA failed to affect PMN migration. Both D1-like DRD5 expression and DA-induced inhibition of PMN migration were however restored after recovery. Dopaminergic inhibition of human PMN is a novel mechanism which is likely to play a key role in the regulation of innate immunity. Evidence obtained in Pts with bacterial infections provides novel clues for the therapeutic modulation of PMN during infectious disease., (© 2022 The Authors. Immunology published by John Wiley & Sons Ltd.)

Published
2022
Full Text
View/download PDF

48. Detection of Torquetenovirus and Redondovirus DNA in Saliva Samples from SARS-CoV-2-Positive and -Negative Subjects.

Author

Spezia PG, Baj A, Drago Ferrante F, Boutahar S, Azzi L, Genoni A, Dalla Gasperina D, Novazzi F, Dentali F, Focosi D, and Maggi F

Subjects
Humans, SARS-CoV-2 genetics, Saliva, Viral Load, DNA, Viral analysis, Torque teno virus genetics, DNA Virus Infections, COVID-19 epidemiology
Abstract

Objectives: Torquetenovirus (TTV) and Redondovirus (ReDoV) are the most prevalent viruses found in the human respiratory virome in viral metagenomics studies. A large-scale epidemiological study was performed to investigate their prevalence and loads in saliva samples according to SARS-CoV-2 status., Methods: Saliva samples from 448 individuals (73% SARS-CoV-2 negative and 27% SARS-CoV-2 positive) aged 23-88 years were tested. SARS-CoV-2 and TTV were determined in saliva by specific qualitative and quantitative real-time PCRs, respectively. A sub-cohort of 377 subjects was additionally tested for the presence and load of ReDoV in saliva, and a different sub-cohort of 120 subjects for which paired saliva and plasma samples were available was tested for TTV and ReDoV viremia at the same timepoints as saliva., Results: TTV in saliva was 72% prevalent in the entire cohort, at a mean DNA load of 4.6 log copies/mL, with no difference regardless of SARS-CoV-2 status. ReDoV was found in saliva from 61% of the entire cohort and was more prevalent in the SARS-CoV-2-negative subgroup (65% vs. 52%, respectively). In saliva, the total mean load of ReDoV was very similar to the one of TTV, with a value of 4.4 log copies/mL. The mean viral loads in subjects infected with a single virus, namely, those infected with TTV or ReDoV alone, was lower than in dually infected samples, and Tukey's multiple-comparison test showed that ReDoV single-infected samples resulted in the only true outlier ( p = 0.004). Differently from TTV, ReDoV was not detected in any blood samples., Conclusions: This study establishes the prevalence and mean value of TTV and ReDoV in saliva samples and demonstrates the existence of differences between these two components of the human virome.

Published
2022
Full Text
View/download PDF

49. Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications.

Author

Potere N, Del Buono MG, Caricchio R, Cremer PC, Vecchié A, Porreca E, Dalla Gasperina D, Dentali F, Abbate A, and Bonaventura A

Subjects
Humans, NLR Family, Pyrin Domain-Containing 3 Protein metabolism, Interleukin 1 Receptor Antagonist Protein, SARS-CoV-2, Interleukin-1beta metabolism, Inflammasomes metabolism, COVID-19 complications, COVID-19 Drug Treatment
Abstract

A hyperinflammatory response during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection crucially worsens clinical evolution of coronavirus disease 2019 (COVID-19). The interaction between SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2) triggers the activation of the NACHT, leucine-rich repeat, and pyrin domain-containing protein 3 (NLRP3) inflammasome. Enhanced inflammasome activity has been associated with increased disease severity and poor prognosis. Evidence suggests that inflammasome activation and interleukin-1β (IL-1β) release aggravate pulmonary injury and induce hypercoagulability, favoring progression to respiratory failure and widespread thrombosis eventually leading to multiorgan failure and death. Observational studies with the IL-1 blockers anakinra and canakinumab provided promising results. In the SAVE-MORE trial, early treatment with anakinra significantly shortened hospital stay and improved survival in patients with moderate-to-severe COVID-19. In this review, we summarize current evidence supporting the pathogenetic role of the NLRP3 inflammasome and IL-1β in COVID-19, and discuss clinical trials testing IL-1 inhibition in COVID-19., Competing Interests: Declaration of interests PCC has been on scientific advisory committees for Kiniksa Pharmaceuticals Ltd., Bristol Myers Squibb and Sobi and has received grants from Kiniksa Pharmaceuticals Ltd. and Novartis. AV received a travel grant from Kiniksa Pharmaceuticals Ltd. to attend the 2019 AHA Scientific Sessions and honoraria from Effetti s.r.l. (Milan, Italy) to collaborate on the medical website www.inflammology.org. AA received research support from Kiniksa Pharmaceuticals Ltd., Novartis, Olatec, R-Pharm, Serpin Pharma, served as an advisor to Abiomed, Applied Clinical Intel, Cromos Pharma, Eli Lilly, Implicit Bioscience, Janssen, and Novo-Nordisk, and has received honoraria from Effetti s.r.l. (Milan, Italy) and Kiniksa Pharmaceuticals Ltd. for educational events. AB received a travel grant from Kiniksa Pharmaceuticals Ltd. to attend the 2019 AHA Scientific Sessions and honoraria from Effetti s.r.l. (Milan, Italy) to collaborate on the medical website www.inflammology.org. The remaining authors have nothing to disclose related to this study., (Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)

Published
2022
Full Text
View/download PDF

50. Reply to the Letter to the Editor: "Importance of nasal secretions in the evaluation of mucosal immunity elicited by mRNA BNT162b2 COVID-19 vaccine" by Francavilla B et al.: Lack of a strong oral mucosal immune response: rethinking the route of COVID-19 vaccine boost administration?

Author

Azzi L, Dalla Gasperina D, Accolla RS, and Forlani G

Subjects
BNT162 Vaccine, Humans, Immunity, Mucosal, RNA, Messenger, COVID-19 prevention & control, COVID-19 Vaccines
Abstract

Competing Interests: Declaration of interests The authors declare no conflict of interest.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results